Janux Therapeutics Announces Proposed Public Offering of Common Stock
27 Fevereiro 2024 - 7:00PM
Business Wire
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a
clinical-stage biopharmaceutical company developing a broad
pipeline of novel immunotherapies by applying its proprietary
technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor
Activated Immunomodulator (TRACIr) platforms, today announced that
it has commenced an underwritten public offering of $175.0 million
of shares of its common stock. In addition, Janux expects to grant
the underwriters a 30-day option to purchase up to an additional
$26.25 million of shares of its common stock at the public offering
price, less the underwriting discounts and commissions. All of the
shares to be sold in the offering are to be sold by Janux. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
BofA Securities, TD Cowen, Cantor Fitzgerald & Co. and
William Blair & Company, L.L.C. are acting as joint
book-running managers for the offering.
The Company intends to use the net proceeds from the offering to
advance clinical development of its internal product pipeline and
for general corporate purposes.
The shares are being offered by the company pursuant to a
Registration Statement on Form S-3 previously filed and declared
effective by the Securities and Exchange Commission (SEC). A
preliminary prospectus supplement and accompanying prospectus
relating to the offering will be filed with the SEC and will be
available on the SEC’s website, located at www.sec.gov. Copies of
the preliminary prospectus supplement and the accompanying
prospectus relating to this offering may be obtained, when
available, from: BofA Securities, NC1-022-02-25, 201 North Tryon
Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus
Department, or by email at dg.prospectus_requests@bofa.com; Cowen
and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by
email at Prospectus_ECM@cowen.com or by telephone at (833)
297-2926; Cantor Fitzgerald & Co., Attention: Capital Markets,
110 East 59th Street, 6th Floor, New York, NY 10022, or by email at
prospectus@cantor.com; or William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email
at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Janux Therapeutics, Inc.
Janux is a clinical-stage biopharmaceutical company developing
tumor-activated immunotherapies for cancer. Janux’s proprietary
technology enabled the development of two distinct bispecific
platforms: TRACTr and TRACIr. The goal of both platforms is to
provide cancer patients with safe and effective therapeutics that
direct and guide their immune system to eradicate tumors while
minimizing safety concerns. Janux is currently developing a broad
pipeline of TRACTr and TRACIr therapeutics directed at several
targets to treat solid tumors. Janux has two TRACTr therapeutic
candidates in clinical trials, the first targeting PSMA is in
development for prostate cancer, and the second targeting EGFR is
being developed for colorectal, lung, head and neck, and renal
cancers.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, the timing, size, terms and
completion of the proposed public offering, the anticipated use of
proceeds therefrom and the grant of the option to purchase
additional shares. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
forward-looking statements are based upon Janux’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without
limitation, risks and uncertainties associated with market
conditions, the satisfaction of customary closing conditions
related to the proposed public offering, and the other risks
described in Janux’s filings with the SEC. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Janux undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227489330/en/
Investors: Andy Meyer Janux Therapeutics ameyer@januxrx.com
(202) 215-2579
Media: Jessica Yingling, Ph.D. Little Dog Communications Inc.
jessica@litldog.com (858) 344-8091
Janux Therapeutics (NASDAQ:JANX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Janux Therapeutics (NASDAQ:JANX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024